Dear Ms. Percival:

Please refer to your supplemental new drug application dated January 5, 2009, received January 5, 2009, submitted under section 505(b) of the Federal, Food, Drug, and Cosmetic Act (FDCA) for REYATAZ® (atazanavir sulfate) 100mg, 150 mg, 200 mg, and 300 mg capsules.


This supplemental new drug application updates the package insert with the 96 week results from the antiretroviral treatment-naive adult Study AI424-138.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to enclosed labeling (text for the package insert, text for the patient package insert). For administrative purposes, please designate this submission, “SPL for approved NDA 021567/S-019”.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

    MedWatch
    Food and Drug Administration
    5600 Fishers Lane, Room 12B05
    Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherly Abraham, R.Ph., Regulatory Project Manager, at (301)796-3198 or 301-796-1500.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosures

    Package Insert
    Patient Package Insert
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-21567</td>
<td>SUPPL-19</td>
<td>BRISTOL MYERS SQUIBB CO</td>
<td>REYATAZ (ATAZANAVIR SULFATE)</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHERLY ABRAHAM
11/05/2009

JEFFREY S MURRAY
11/05/2009